Document is current
Any future updates will be listed below
-
Authors
Strauss, Alexandra
Swann, Peter
Kigar, Stacey L. https://orcid.org/0000-0003-2636-0648
Christou, Rafailia
Savinykh Yarkoni, Natalia
Turner, Lorinda
Murley, Alexander G.
Chouliaras, Leonidas https://orcid.org/0000-0002-3052-3879
Shapiro, Noah https://orcid.org/0000-0002-7786-2747
Ashton, Nicholas J.
Savulich, George https://orcid.org/0000-0002-6513-5454
Bevan-Jones, W. Richard
Surendranthan, Ajenthan
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
O’Brien, John T. https://orcid.org/0000-0002-0837-5080
Rowe, James B. https://orcid.org/0000-0001-7216-8679
Malpetti, Maura https://orcid.org/0000-0001-8923-9656
- License Information
-
More Information
Article History
Received: 16 January 2024
Revised: 18 October 2024
Accepted: 22 October 2024
First Online: 29 October 2024
Competing interests
: The authors have no conflicts of interest to report related to this work. Unrelated to this work, JTO has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai and Novo Nordisk, and has acted as a consultant for Biogen and Roche, and has received research support from Alliance Medical and Merck. JBR is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy unrelated to the current work to Asceneuron, Alector, Astronautx, Astex, Curasen, ClinicalInk, CumulusNeuro, Wave, SVHealth, and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK. M.M. has acted as a consultant for Astex Pharmaceuticals. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
